News

Bayer and LANXESS sell their stakes in the chemical park operator Currenta to funds managed by Macquarie Infrastructure and Real Assets (MIRA), the world's largest infrastructure…
Read More...

Roche announced that the Phase III IMvigor130 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS). The combination of Tecentriq (atezolizumab)…
Read More...

Eli Lilly and Company announced that Emgality (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety of…
Read More...

HCL Technologies (HCL), a leading global technology company and a Platinum-Level member of Oracle Partner Network (OPN), and Oracle Health Sciences announced a collaboration to help…
Read More...

Neuropore Therapies, Inc. announced that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were…
Read More...

Foamix Pharmaceuticals Ltd., a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in…
Read More...

Sosei Group Corporation announces that it has entered into a strategic multi-target partnership with Takeda Pharmaceutical Company Limited, to discover, develop and commercialize novel…
Read More...

Alnylam Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for givosiran, an investigational RNAi…
Read More...

Telix Pharmaceuticals Limited, a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or…
Read More...

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) approved TURALIO (pexidartinib) as the first and only treatment…
Read More...

Omeros Corporation announced a long-term manufacturing agreement for commercial production of narsoplimab, Omeros’ lead human monoclonal antibody targeting mannan-binding…
Read More...

Lyophilization Services of New England (LSNE), a leading contract development and manufacturing organization, continues their expansion with the addition of increased cGMP storage…
Read More...

Samsung BioLogics (SBL) and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB's anti-tau candidate to treat progressive…
Read More...

The U.S. Food and Drug Administration (FDA) approved Nubeqa (darolutamide), an androgen receptor inhibitor (ARi), for the treatment of patients with non-metastatic castration-resistant…
Read More...

Pfizer Inc. announced the closing of its joint venture with GlaxoSmithKline plc to combine the parties’ respective consumer healthcare businesses to create the world’s largest…
Read More...

Endo International plc announced the appointment of Domenic Ciarico as Executive Vice President and Chief Commercial Officer, Sterile and Generics, effective immediately. In this…
Read More...

Marken announced the acquisition of PCX International Co. Ltd based in Japan. PCX operates from their Tokyo headquarters to coordinate the delivery of over 3,000 clinical trial…
Read More...

Pfenex Inc. and Arcellx, Inc. announced a Development, Evaluation and License agreement under which Arcellx gains access to the proprietary Pfenex Expression Technology platform to…
Read More...

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced that the University of Delaware, on behalf of NIIMBL, has entered into a Collaborative…
Read More...

Cambrex Corporation announced that it is expanding its solid form screening and crystallization process development facility in Edinburgh, Scotland, doubling the current footprint to…
Read More...